Works matching IS 01676997 AND DT 2014 AND VI 32 AND IP 4
Results: 27
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 618, doi. 10.1007/s10637-014-0098-1
- By:
- Publication type:
- Article
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 644, doi. 10.1007/s10637-014-0072-y
- By:
- Publication type:
- Article
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 753, doi. 10.1007/s10637-014-0093-6
- By:
- Publication type:
- Article
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 604, doi. 10.1007/s10637-014-0084-7
- By:
- Publication type:
- Article
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 670, doi. 10.1007/s10637-014-0082-9
- By:
- Publication type:
- Article
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 626, doi. 10.1007/s10637-014-0108-3
- By:
- Publication type:
- Article
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 717, doi. 10.1007/s10637-014-0104-7
- By:
- Publication type:
- Article
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 636, doi. 10.1007/s10637-014-0068-7
- By:
- Publication type:
- Article
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 729, doi. 10.1007/s10637-014-0078-5
- By:
- Publication type:
- Article
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 577, doi. 10.1007/s10637-014-0095-4
- By:
- Publication type:
- Article
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 598, doi. 10.1007/s10637-014-0076-7
- By:
- Publication type:
- Article
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 710, doi. 10.1007/s10637-014-0096-3
- By:
- Publication type:
- Article
Kidney injuries related to ipilimumab.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 769, doi. 10.1007/s10637-014-0092-7
- By:
- Publication type:
- Article
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 653, doi. 10.1007/s10637-014-0071-z
- By:
- Publication type:
- Article
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 723, doi. 10.1007/s10637-014-0077-6
- By:
- Publication type:
- Article
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 762, doi. 10.1007/s10637-014-0097-2
- By:
- Publication type:
- Article
Dysphonia induced by anti-angiogenic compounds.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 774, doi. 10.1007/s10637-013-0049-2
- By:
- Publication type:
- Article
Evaluation of two I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 587, doi. 10.1007/s10637-014-0086-5
- By:
- Publication type:
- Article
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 746, doi. 10.1007/s10637-014-0091-8
- By:
- Publication type:
- Article
Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 661, doi. 10.1007/s10637-014-0080-y
- By:
- Publication type:
- Article
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 739, doi. 10.1007/s10637-014-0083-8
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 691, doi. 10.1007/s10637-014-0094-5
- By:
- Publication type:
- Article
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 682, doi. 10.1007/s10637-014-0088-3
- By:
- Publication type:
- Article
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 700, doi. 10.1007/s10637-014-0089-2
- By:
- Publication type:
- Article